Parabilis Medicines, INC

Parabilis Medicines, Inc. announced its intention to present updated clinical data for zolucatetide in desmoid tumor patients at the ESMO Congress 2026.

Parabilis Medicines announced the appointment of Craig L. Tendler, M.D., an accomplished drug development leader with extensive oncology experience, to its Board of Directors.

Parabilis Medicines announced strong Q2 2026 results, highlighting advancements in zolucatetide trials, a major collaboration with Regeneron, and a robust cash position extending runway to 2030.

Craig Tendler, a Director of Parabilis Medicines, Inc., received 20,294 shares of common stock on August 22, 2026.

Ra Capital Management, L.P. and 4 others reported changes in beneficial ownership of Parabilis Medicines, Inc. common stock on July 20, 2026.

SEC Form 4 filing reveals significant stock transactions by Guy Levy and associated Soleus entities on June 11, 2026.

FMR LLC, through its subsidiaries, has disclosed beneficial ownership of 8.5% of Parabilis Medicines Inc.'s common stock as of June 30, 2026.